Fulgent Reports Third Quarter 2025 Financial Results
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Business Wire
Revenue of $84.1 million, growing 17% year-over-yearRaising Full Year 2025 Revenue Guidance to $325.0 millionRaising Full Year 2025 EPS Guidance to GAAP loss of approximately ($1.70) per share and Non-GAAP income of $0.30 per shareGAAP gross profit of $35.5 million, or GAAP gross margin of 42.2%; Non-GAAP gross profit of $37.2 million, or Non-GAAP gross margin of 44.3%GAAP loss of $6.6 million, or ($0.21) per share; Non-GAAP income of $4.5 million, or $0.14 per shareEnded third quarter with $787.7 million of cash, cash equivalents, restricted cash, and investments in marketable securities EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025.Third Quarter 2025 Results:Revenue of $84.1 million, growing 17% year-over-yearGAAP loss of $6.
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating [Seeking Alpha]Seeking Alpha
- Fulgent Genetics (NASDAQ:FLGT) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Fulgent Genetics (NASDAQ:FLGT) had its price target raised by analysts at Piper Sandler from $21.00 to $30.00. They now have a "neutral" rating on the stock.MarketBeat
- Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Fulgent Genetics Inc (FLGT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Upward ... [Yahoo! Finance]Yahoo! Finance
FLGT
Earnings
- 11/7/25 - Beat
FLGT
Analyst Actions
- 11/14/25 - Raymond James Financial, Inc.
FLGT
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- FLGT's page on the SEC website